Скачать или смотреть BEAM-302 Gets FDA Orphan Drug Status | Beam Therapeutics’ AATD Therapy Explained

Greetings, fellow investors! Welcome back to ShareTreck. Beam Therapeutics just secured orphan drug designation for BEAM-302, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). In this ShareTreck deep dive, Raj breaks down what the FDA decision means, how BEAM-302 works, and the market opportunity in this $9.28B rare disease space.
#BeamTherapeutics #BEAM302 #AATD #GeneEditing #BaseEditing #CRISPR #BiotechInvesting

Please let me know what you think.

JOIN THE CHANNEL AS A MEMBER:

Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen or copy the link below to your browser address bar and press enter.

   / @sharetreck  

Please subscribe:    / @sharetreck  


The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
In case of coverage of pharma companies, disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.